Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more
Applied BioCode (6598) - Total Liabilities
Latest total liabilities as of September 2025: NT$343.23 Million TWD
Based on the latest financial reports, Applied BioCode (6598) has total liabilities worth NT$343.23 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Applied BioCode - Total Liabilities Trend (2012–2024)
This chart illustrates how Applied BioCode's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Applied BioCode Competitors by Total Liabilities
The table below lists competitors of Applied BioCode ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Panda Financial Holding Corp Ltd
SHG:600599
|
China | CN¥184.45 Million |
|
OCK Group Bhd
KLSE:0172
|
Malaysia | RM1.29 Billion |
|
Galaxy Gaming Inc
OTCQB:GLXZ
|
USA | $45.47 Million |
|
Yusin Holding Corp
TW:4557
|
Taiwan | NT$2.05 Billion |
|
Sanitar Co Ltd
TW:1817
|
Taiwan | NT$748.65 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$39.34 Million |
|
Sungdo Engineering & Construction Co. Ltd
KQ:037350
|
Korea | ₩301.05 Billion |
|
Tatung System Technologies
TWO:8099
|
Taiwan | NT$2.17 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Applied BioCode's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Applied BioCode's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Applied BioCode (2012–2024)
The table below shows the annual total liabilities of Applied BioCode from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$336.07 Million | +1.16% |
| 2023-12-31 | NT$332.22 Million | -16.19% |
| 2022-12-31 | NT$396.38 Million | +241.68% |
| 2021-12-31 | NT$116.01 Million | -17.27% |
| 2020-12-31 | NT$140.23 Million | -25.55% |
| 2019-12-31 | NT$188.36 Million | +131.55% |
| 2018-12-31 | NT$81.35 Million | +34.89% |
| 2017-12-31 | NT$60.30 Million | +17.84% |
| 2016-12-31 | NT$51.17 Million | +25.81% |
| 2015-12-31 | NT$40.67 Million | +4.37% |
| 2014-12-31 | NT$38.97 Million | +64.93% |
| 2013-12-31 | NT$23.63 Million | +18.18% |
| 2012-12-31 | NT$20.00 Million | -- |